R
R. Bernabé
Researcher at Services Hospital
Publications - 44
Citations - 5361
R. Bernabé is an academic researcher from Services Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 10, co-authored 28 publications receiving 4546 citations.
Papers
More filters
Journal ArticleDOI
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell,Enric Carcereny,Radj Gervais,A. Vergnenegre,Bartomeu Massuti,Enriqueta Felip,Ramon Palmero,Ramon Garcia-Gomez,Cinta Pallares,Jose Miguel Sanchez,Rut Porta,Manuel Cobo,Pilar Garrido,Flavia Longo,Teresa Moran,A. Insa,Filippo de Marinis,Romain Corre,Isabel Bover,Alfonso Illiano,Eric Dansin,Javier de Castro,Michele Milella,Noemi Reguart,Giuseppe Altavilla,Ulpiano Jimenez,Mariano Provencio,Miguel Angel Moreno,J. Terrasa,Jose Muñoz-Langa,Javier Valdivia,Dolores Isla,Manuel Domine,Olivier Molinier,Julien Mazieres,Nathalie Baize,Rosario García-Campelo,Gilles Robinet,Delvys Rodriguez-Abreu,Guillermo Lopez-Vivanco,Vittorio Gebbia,Lioba Ferrera-Delgado,Pierre Bombaron,R. Bernabé,Alessandra Bearz,Angel Artal,Enrico Cortesi,Christian Rolfo,Maria Sanchez-Ronco,Ana Drozdowskyj,Cristina Queralt,Itziar de Aguirre,Jose Luis Ramirez,Jose Javier Sanchez,Miguel Angel Molina,Miquel Taron,Luis Paz-Ares +56 more
TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.
Journal ArticleDOI
Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection: The Phase 2 DURVAST Study
Maria Gonzalez-Cao,Teresa Moran,Judith Dalmau,Javier Garcia-Corbacho,Jillian Wilhelmina Paulina Bracht,R. Bernabé,Oscar Juan,Javier de Castro,R. Blanco,Ana Drozdowskyj,Jordi Argilaguet,Andreas Meyerhans,Andreas Meyerhans,Julià Blanco,Julia G. Prado,Jorge Carrillo,Bonaventura Clotet,Bartomeu Massuti,Mariano Provencio,Miguel Angel Molina-Vila,Clara Mayo de las Casa,Mónica Garzón,Peng Cao,Chung-Ying Huang,Javier Martinez-Picado,Rafael Rosell +25 more
TL;DR: Durvalumab treatment was feasible and safe in HIV-1-infected patients with cancer receiving combination antiretroviral therapy and patients on suppressive antifiltration therapy with advanced cancer should have access to cancer immunotherapy treatments.
Journal ArticleDOI
Neoadjuvant chemo-immunotherapy for the treatment of stage IIIA resectable non-small-cell lung cancer (NSCLC): A phase II multicenter exploratory study—Final data of patients who underwent surgical assessment.
Mariano Provencio,Ernest Nadal,Amelia Insa,Rosario García-Campelo,Joaquin Casal Rubio,Manuel Domine,Margarita Majem,Delvys Rodriguez-Abreu,Alex Martinez Marti,Manuel Cobo,Guillermo Lopez-Vivanco,Elvira del Barco,R. Bernabé,Nuria Viñolas,Isidoro Barneto,Santiago Viteri,Paloma Martín-Martorell,Maria Jove,F. Franco,Bartomeu Massuti +19 more
TL;DR: Patients with stage IIIA (N2 or T4N0) are potentially curable but median overall survival is only around 15 months and complete pathologic response with conventional chemotherapy (C...
Journal ArticleDOI
Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study—NADIM study-SLCG.
Mariano Provencio-Pulla,Ernest Nadal-Alforja,Manuel Cobo,Amelia Insa,Marinha Costa Rivas,Margarita Majem,Delvys Rodriguez-Abreu,Guillermo Lopez-Vivanco,Manuel Domine,Elvira Del Barco Morillo,Bartomeu Massuti,Rosario Garcia Campelo,Alexandre Martinez Marti,R. Bernabé,Fernando Franco,Maria Jove,Ricardo Arrabal,Paloma Martín,J. Casal,Virginia Calvo +19 more
TL;DR: A novel chemotherapy and immunotherapy combination has a high response rate and longer survival in unselected patients with metastatic non-small cell lung cancer (NSCLC) and is suitable for use in combination with conventional chemotherapy.
Journal ArticleDOI
Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping
Jon Zugazagoitia,Israel Ramos,Jose Manuel Trigo,Magda Palka,Ana Gómez-Rueda,Eloisa Jantus-Lewintre,Carlos Camps,Dolores Isla,P. Iranzo,Santiago Ponce-Aix,Rosario García-Campelo,Mariano Provencio,F. Franco,R. Bernabé,O. Juan-Vidal,Enriqueta Felip,J. de Castro,José Miguel Sánchez-Torres,I. Faul,Richard B. Lanman,Pilar Garrido,Luis Paz-Ares +21 more
TL;DR: Digital NGS of ctDNA in lung cancers with insufficient tumor samples for tissue sequencing detects actionable variants that frequently co-occur with other potentially clinically relevant genomic alterations, allowing timely initiation of genotype-matched therapies.